ABSTRACT
Background: The objective of this study was to assess the efficacy of Riboflavin as a prophylactic agent for migraine in comparison to the established agent, a beta blocker, Propranolol. Methods: 120 patients were grouped randomly into 3 groups after taking demographic details. One group (Group I) was given 80mg/day of Propranolol, second group (Group II) was given 100mg/day riboflavin and the third group (Group III) was given placebo. Frequency and duration of headaches, Visual Analogue scale (VAS) and Migraine disability assessment (MIDAS) score were taken at base line of treatment and at 1st month, 3rd month and 6th month of follow up. Results: The mean age of the patients in the study was 35.1 years ± 3.5 years. There was not much difference in the age of the patients and gender between the 3 groups. Neither was the incidence of family history in the three groups. The frequency of headaches reduced in one month from 3.9 to 3.1 with propranolol compared to riboflavin(3.8-3.2) but in the 3rd month and 6th month riboflavin showed a better effect than propranolol though propranolol was almost as effective (2.7 and 2.4 respectively). In the Riboflavin group, the duration of headaches reduced from 3.2 days at base line to 2.5 at the first month to 2 days in the 6th month, while in propranolol group, the reduction was from 3.1 at base line to 2.6 in the first month to 2 days in the 6th month. VAS and MIDAS were comparable in both the groups. There were more side effects like dizziness and fatigue in th Propranolol group while only orange coloured urine was the complication in the Riboflavin group. Conclusion: Riboflavin is comparable to Propranolol in the prophylaxis of migraine. Since it is cost effective as well as non toxic, it can be used instead of Propranolol which has quite a few side effects.
ABSTRACT
Background: Uncomplicated cataract procedures have become very easy to perform with minimal complications. Treatment of inflammation post-surgery was usually by corticosteroides. Of late, Diclofenac sodium, a non-steroid anti- inflammatory agent is being widely tested to be used instead of corticosteroids as steroids are known for their side effects. Methods: 179 patients of both genders, undergoing elective unilateral ECCE with IOL implantation were included into this study. The patients were divided into 2 groups. Group 1 consisted of 89 patients who were given diclofenac sodium and Group 2 of 90, who were treated with dexamethasone post operatively. All patients were subjected to visometric, eye biomicroscopic, ophthalmoscopic and tonometric examination before surgery and on 1st, 3rd, 7th and 14the days post-surgery. Results: By 7th day, the visual acuity was 75% in group 1 and 695 IN Group 2. Inflammation was seen in less than 8% of the cases in both the groups showing that both the drugs are equally efficient. Conclusion: As diclofenac is as good as dexamethasone, if not better, dicofenac can be used in lieu of the latter for the treatment of inflammation in uncomplicated cataract surgeries.